Pharmaceutical Executive-02-01-2011

Issue PDF
Pharmaceutical Executive

February 01, 2011

The Promise Of Translational Medicine

Pharmaceutical Executive

Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story

Pharmaceutical Executive
Features

February 01, 2011

If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country

Pharmaceutical Executive
Columns

February 01, 2011

Adapting training techniques is necessary to thrive in the fact-changing dynamic of a physician's office

Pharmaceutical Executive
Features

February 01, 2011

With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?

Pharmaceutical Executive

Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities

Pharmaceutical Executive
Columns

February 01, 2011

To manage through a resource-constrained environment, it is essential to get the most out of procurement planning

Pharmaceutical Executive

What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light

Pharmaceutical Executive
Columns

February 01, 2011

The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency

Pharmaceutical Executive

All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.

Pharmaceutical Executive
Columns

February 01, 2011

With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace